Mylan Announces Approval for Metformin Hydrochloride Extended-release Tablets, 500 mg and 750 mg

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Metformin Hydrochloride Extended-release Tablets, 500 mg and 750 mg. Metformin HCl ER Tablets, which are the generic version of Bristol-Myers Squibb's Glucophage® XR Tablets, 500 mg and 750 mg, had U.S. sales of approximately $173 million, for the 12-month period ending June 30, 2005, according to IMS.

This product will be available soon.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the availability of Metformin Hydrochloride ER. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.
09/14/2005
CONTACT: Media, Patrick Fitzgerald, or Investors, Kris King, of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)